Experienced in Geographic Atrophy

Dr. Christine N. Kay

Ophthalmology
Vitreo Retinal Associates PA
4340 Newberry Rd, Suite 202, 
Gainesville, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Geographic Atrophy
Vitreo Retinal Associates PA
4340 Newberry Rd, Suite 202, 
Gainesville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christine Kay is an Ophthalmologist in Gainesville, Florida. Dr. Kay is rated as an Experienced provider by MediFind in the treatment of Geographic Atrophy. Her top areas of expertise are Color Blindness, Retinitis Pigmentosa, Retinopathy Pigmentary Mental Retardation, Late-Onset Retinal Degeneration, and Vitrectomy. Dr. Kay is currently accepting new patients.

Her clinical research consists of co-authoring 47 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Florida College Of Medicine
Specialties
Ophthalmology
Licenses
Ophthalmology in FL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

VITREO RETINAL ASSOCIATES PA
4340 Newberry Rd, Suite 202, Gainesville, FL 32607

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration
A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration
Enrollment Status: Recruiting
Publish Date: September 15, 2025
Intervention Type: Biological
Study Drugs: 4D-150, Aflibercept
Study Phase: Phase 1/Phase 2
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Enrollment Status: Enrolling_by_invitation
Publish Date: April 27, 2025
Intervention Type: Drug
Study Drug: ALK-001
Study Phase: Phase 2
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene
Enrollment Status: Active_not_recruiting
Publish Date: March 21, 2025
Intervention Type: Biological, Other
Study Drug: 4D-125
Study Phase: Phase 1/Phase 2
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drug: AGTC-402
Study Phase: Phase 1/Phase 2
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drug: rAAV2tYF-PR1.7-hCNGB3
Study Phase: Phase 1/Phase 2
A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene
A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2022
Intervention Type: Drug, Other
Study Drug: QR-1123
Study Phase: Phase 1/Phase 2
Clinical and Genetic Characterization of Individuals With Achromatopsia
Clinical and Genetic Characterization of Individuals With Achromatopsia
Enrollment Status: Completed
Publish Date: October 13, 2017
View 6 Less Clinical Trials

47 Total Publications

Atypical presentation of Oguchi disease with severe cystoid macular edema and compound heterozygous SAG pathogenic variants.
Atypical presentation of Oguchi disease with severe cystoid macular edema and compound heterozygous SAG pathogenic variants.
Journal: Ophthalmic genetics
Published: October 19, 2025
Similar Doctors
Distinguished in Geographic Atrophy
Dr. Remington I. Horesh
Ophthalmology
Distinguished in Geographic Atrophy
Dr. Remington I. Horesh
Ophthalmology

St Lukes At The Villages PA

1050 Old Camp Rd, Suite 230, 
The Villages, FL 
 (55.2 miles away)
352-350-8484
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Remington Horesh is an Ophthalmologist in The Villages, Florida. Dr. Horesh is rated as a Distinguished provider by MediFind in the treatment of Geographic Atrophy. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, and Retinal Artery Occlusion. Dr. Horesh is currently accepting new patients.

Advanced in Geographic Atrophy
Dr. Fred H. Lambrou
Ophthalmology
Advanced in Geographic Atrophy
Dr. Fred H. Lambrou
Ophthalmology
2 Shircliff Way Ste 715, 
Jacksonville, FL 
 (61.4 miles away)
904-388-8446
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients

Fred Lambrou is an Ophthalmologist in Jacksonville, Florida. Dr. Lambrou is rated as an Advanced provider by MediFind in the treatment of Geographic Atrophy. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, and Retinal Detachment. Dr. Lambrou is currently accepting new patients.

Advanced in Geographic Atrophy
Dr. Robert J. Kraut
Ophthalmology
Advanced in Geographic Atrophy
Dr. Robert J. Kraut
Ophthalmology

Ocala Eye PA

4414 Sw College Rd, Unit 1462, 
Ocala, FL 
 (37.7 miles away)
352-622-5183
Languages Spoken:
English, French, German, Greek, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Kraut is an Ophthalmologist in Ocala, Florida. Dr. Kraut is rated as an Advanced provider by MediFind in the treatment of Geographic Atrophy. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, and Retinal Artery Occlusion. Dr. Kraut is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kay's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 8 Advanced Conditions
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile